Table of Contents Pharma news – 9 July 2020 Mylan gears up to sell its generic version of Remdesivir at 4,800 rupees in India: Cipla and Hetero labs began the sale of their generic version of Remdesivir in India in June 2020. Hetero priced its generic version, Covifor at 5,400 rupees. Cipla however claimed that […]
Pharma News – 9 July 2020 Updates Read More »
Indian Government is reviewing the use of Remdesivir for Covid-19 following reports of liver damage The Union Health Ministry of India is currently reviewing the use of Remdesivir in the country. Multiple reports of liver damage in the Covid-19 patients treated with this drug have instigated this action. The side-effects of Remdesivir was one of
Pharma news – 5 July 2020 Read More »
Sun Pharma launches Ilumya in the Japanese market Sun Pharma had announced the launch of its psoriasis drug, Ilumya, in the Japanese market on 29 June 2020. Ilumya is an innovative product of Sun Pharma that is used for plaque psoriasis.The drug firm has stated that one of its wholly-owned subsidiaries in Japan had received
Pharma News – 2 July 2020 Read More »
1. Hindustan Antibiotic’s moves to explore opportunities in line with self-reliant India Around 70% of the active pharmaceutical ingredients (API) needed for the production of important drugs in India are imported from China. However, the current volatility between the two countries has instilled fear and uncertainty in the minds of everyone. To reduce this dependency,
Pharma News – 28 June 2020 Read More »
India plans to reduce the import of API and other raw materials from China The military face-off between India and China has put both the countries in a frenzy. To prevent things from escalating downhill, both countries have resorted to talking things out smoothly. But despite this, precautionary measures are being adopted from both sides
Pharma news – 25 June 2020 Read More »
Glenmark gets USFDA approval for its Fingolimod capsules: Glenmark Pharmaceuticals received the USFDA’s[1] approval for manufacturing the generic version of the 0.5 mg Gilenya capsules. Novartis Pharmaceuticals Corporation held the patent rights for Gilenya capsules and on expiry of this patent, other drug firms had begun to apply to the USFDA for marketing the generic
Pharma News – 22 June 2020 Read More »
USFDA revokes the special status given to Hydroxychloroquine for treating Covid-19 In March 2020, the US[1] president, Donald Trump began to advocate the use of Hydroxychloroquine and azithromycin for treating Covid-19. His persuasive speech backed up by his claim of taking Hydroxychloroquine regularly won the trust of the entire country. This subsequently increased the demand
Pharma News – 18 June 2020 Read More »
Gilead signs licensing pacts with four more drug firms for manufacturing Remdesivir Pharma news – June 20: Gilead Sciences Ltd has recently been signing pacts with various drug firms for the manufacture and marketing of its antiviral drug, #Remdesivir. This drug had received emergency use authorization (EUA) in many countries for treating Covid-19. This decision
Pharma news – June 20 Updates Read More »
Indian Government lifts ban on the export of Hydroxychloroquine Pharma news – June 11: On 25 March 2020, the Indian government banned the export of numerous drugs. The anti-malarial drug, Hydroxychloroquine, was also included in this list. However, there were some relaxations allowed for exporting Hydroxychloroquine since many believed it was capable of treating Covid-19.
Pharma News Updates – June 11, 2020 Read More »
Sun pharma starts phase 2 clinical trials of a plant-derived drug for Covid-19 The phytopharmaceutical (plant-derived) drug, Aquilegia chrysantha (AQCH) is currently being tested for its efficacy against Covid-19. This drug was initially developed for dengue. Owing to its broad antiviral activity, it is now being considered as a possible treatment option for Covid-19. Sun
Pharma news – 8 June, 2020 Read More »
